FDA clears generic versions of Abbott's Depakote

07/30/2008 | Bloomberg

Eight drugmakers -- including Novartis AG and Teva Pharmaceutical Industries -- obtained FDA approval to market copies of Depakote DR, a delayed-release treatment for epilepsy, bipolar disorder and migraines from Abbott Laboratories. The generic treatments will have the same safety label as the brand-name version, including a "black box" warning about the risk of death from liver injury or pancreas inflammation.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN